Renal outcomes of both treatment groups. by Marwan El-Deyarbi (21688492)

“…</p><p>Results</p><p>During a mean follow-up of 11.9 months, 40.4% of the participants in the intervention group (31.6% in the control group) achieved diabetes control (HbA1c < 7%), with a significant mean difference of −0.36% in HbA1c levels between the groups (95% CI: −0.54 – −0.19, P < 0.01). …”

Effect of busulfan treatment on androgens and androgen receptors. by Lingjun Zhao (21763122)

“…<p>Enzyme-linked immunosorbent assay results for A) androgens and B) androgen receptors. The androgen concentration remains stable after busulfan treatment, but the androgen receptor concentration significantly decreases 21 days after treatment. …”

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

Forest plot showing the mean difference of global IQ level among pediatric brain cancer patients treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

PLE inhibits IMQ-induced inflammatory in mice, and the contents of TNF-α (A) and IL-17A (B). by Xiaoqiang Huang (1457860)

Presentation 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.pdf by Yi Li (1144)

“…</p>Conclusion<p>Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy.…”

Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

“…The FMT group also showed a significant reduction in urinary 5-hydroxyindoleacetic acid (5-HIAA) levels from 8.6 to 7.32 mg/L (p = 0.022), while other metabolites showed no significant changes.…”

Effect of <i>slc43a3</i> deletion on resting blood pressure (systolic and diastolic) and heart rate of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Phase analysis data and within group correlations. by Aaron L. Sayler (19797446)

Subjects:

Summary of measured parameters. by Aaron L. Sayler (19797446)

Subjects:

Raw data. by Aaron L. Sayler (19797446)

Subjects:

Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: